Personalis Research and Development Expenses 2018-2024 | PSNL

Personalis research and development expenses from 2018 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.
Personalis Annual Research and Development Expenses
(Millions of US $)
2023 $65
2022 $65
2021 $49
2020 $29
2019 $22
2018 $14
2017 $10
Personalis Quarterly Research and Development Expenses
(Millions of US $)
2024-09-30 $12
2024-06-30 $13
2024-03-31 $13
2023-12-31 $14
2023-09-30 $17
2023-06-30 $18
2023-03-31 $17
2022-12-31 $17
2022-09-30 $15
2022-06-30 $16
2022-03-31 $17
2021-12-31 $15
2021-09-30 $14
2021-06-30 $12
2021-03-31 $9
2020-12-31 $9
2020-09-30 $7
2020-06-30 $6
2020-03-31 $6
2019-12-31 $7
2019-09-30 $5
2019-06-30 $4
2019-03-31 $5
2018-12-31
2018-09-30 $4
2018-06-30 $4
2017-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.261B $0.073B
Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.044B 6.25
Dr Reddy's Laboratories (RDY) India $11.978B 22.92
BridgeBio Pharma (BBIO) United States $4.260B 0.00
Bausch Health Cos (BHC) Canada $3.012B 2.18
Amphastar Pharmaceuticals (AMPH) United States $2.097B 12.61
Supernus Pharmaceuticals (SUPN) United States $1.962B 26.71
Taysha Gene Therapies (TSHA) United States $0.434B 30.29
Assembly Biosciences (ASMB) United States $0.098B 0.00
Sol-Gel Technologies (SLGL) Israel $0.012B 0.00
Evoke Pharma (EVOK) United States $0.007B 0.00
Teligent (TLGT) United States $0.000B 0.00